Press release
Gossamer Bio Announces First Quarter 2022 Financial Results and Provides Business Update
- Seralutinib (GB002) completed PAH patient enrollment in Phase 2 TORREY Study - - Topline results from Phase 2 TORREY Study expected in the fourth quarter
About this update from Gossamer Bio, Inc.
[{"type":"text","content":"\n- Seralutinib (GB002) completed PAH patient enrollment in Phase 2 TORREY Study -\n\n- Topline results from Phase 2 TORREY Study expected in the fourth quarter of 2022 -\n\n- Cash, cash equivalents & marketable securities totaled $272 million as of March 31, 2022 -\n\n SAN DIEGO--(BUSINESS WIRE)--\nGossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the first quarter ended March 31, 2022 and provided a business update.\n\n“We are looking forward to the fourth quarter release of topline data from the ongoing Phase 2 TORREY Study, which has now completed enrollment,” said Faheem Hasnain, Co-Founder, Chairman and Chief Executive Officer of Gossamer Bio.\n\n“Additionally, through a recent internal reprioritization and the implementation of certain cost containment measures, we are pleased to see Gossamer’s expected capital runway further extended into the first half of 2024. As part of this reprioritization, we now anticipate moving GB7208 into the clinic in the first half of 2023, pending the TORREY Study results.”\n\nProduct Candidate Updates\n\nSeralutinib (GB002): Inhaled PDGFR, CSF1R and c-KIT Inhibitor for Pulmonary Arterial Hypertension (PAH)\n\n\nEnrollment has completed in the ongoing TORREY Study, a Phase 2 clinical trial in patients with PAH whose disease has progressed despite standard-of-care therapy. The primary endpoint is change in pulmonary vascular resistance from baseline at week 24.\n\n\nTopline data from the TORREY Study are expected in the fourth quarter of 2022.\n\n\nGB5121: Oral, CNS-Penetrant BTK Inhibitor for Primary CNS Lymphoma (PCNSL) and other Rare CNS Malignancies\n\n\nWe expect to initiate the Phase 1b/2 STAR CNS Study in relapsed / refractory PCNSL and other rare CNS malignancies in the second quarter of 2022.\n\n\nGB7208: Oral, CNS-Penetrant BTK Inhibitor for Neuroinflammatory Diseases\n\n\nPending the outcomes of ongoing preclinical studies and the seralutinib Phase 2 TORREY Study topline results, we expect to initiate a Phase 1 clinical trial in healthy volunteers in the first half of 2023.\n\n\nFinancial Results for Quarter Ended March 31, 2022\n\n\nCash, Cash Equivalents and Marketable Se...